Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of therapies targeting cellular metabolism, particularly in cancer and rare genetic disorders. The company offers TIBSOVO, an oral targeted inhibitor approved for treating relapsed or refractory acute myeloid leukemia (AML) and newly diagnosed AML, as well as IDHIFA, which targets AML patients with specific genetic mutations. Agios is advancing multiple clinical programs, including TIBSOVO for frontline AML and cholangiocarcinoma, and developing mitapivat for pyruvate kinase deficiency and thalassemia. Other investigational compounds include vorasidenib for solid tumors and AG-270 for specific cancer types. Agios employs a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for successful early clinical proof of concept and accelerated approvals. The company was originally established in 2007 under the name Cancer Metabolism Therapeutics before rebranding to Agios Pharmaceuticals in 2008.
Symphogen A/S is a clinical late-stage biopharmaceutical company based in Ballerup, Denmark, with an additional operation in Somerville, New Jersey. The company specializes in the development of innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies. Its pipeline includes several promising candidates, such as Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR, and Sym013, designed to inhibit EGFR, HER2, and HER3 simultaneously. Other notable products in development are Sym015, which targets the MET receptor, Sym021, a monoclonal antibody that blocks PD1, and Sym009, an antibody conjugated to an antibiotic for treating specific strains of staphylococcus aureus. Symphogen aims to address various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers, ultimately enhancing treatment efficacy and patient outcomes.